On October 27, 2020, Milestone Pharmaceuticals Inc. completed its $45 million public offering. The offering was made through a syndicate of underwriters with Jefferies and Piper Sandler as joint book running managers for the offering and Oppenheimer & Co. as lead manager. Milestone Pharmaceuticals Inc. will use the proceeds to fund the clinical development of its lead product candidate, etripamil. The proceeds will also be put towards working capital, capital expenditures and for general corporate purposes.
Milestone Pharmaceuticals Inc. is a Montreal based, Phase 3 clinical-stage biopharmaceutical company specializing in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications.
Osler, Hoskin & Harcourt LLP advised Milestone Pharmaceuticals Inc. with a team consisting of Nathalie Beauregard, François Paradis, Jeremy Brisset and Daniel Stysis (Corporate).